Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report
February 8, 2022 7:47 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Good Enough 4Q21 results driven by an EPS beat; 2022 Guide light, but we see room... More
Pfizer (PFE) Reiterated at Overweight by Cantor Fitzgerald, "Confident PFE Can Meet its Guidance for a 5-year Revenue CAGR of at least 6%"
February 8, 2022 7:21 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $75.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Post a mixed 4Q21 report (sales miss, fewer selling days and EPS beat), we are... More
